For the quarter ending 2025-12-31, RMD had $33,221K increase in cash & cash equivalents over the period. $311,206K in free cash flow.
| Cash Flow | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Net income | 392,593 | 348,536 | 379,705 | 365,041 |
| Depreciation and amortization | 49,885 | 47,698 | 63,628 | 43,676 |
| Amortization of right-of-use assets | 12,445 | 9,971 | 10,660 | 8,235 |
| Stock-based compensation costs | 28,938 | 21,160 | 24,751 | 24,120 |
| (gain) loss attributable to equity method investments, net of dividends received (note 6) | - | - | 3,644 | - |
| (gain) loss attributable to equity method investments (note 5) | 1,515 | -886 | - | 335 |
| (gain) loss on equity investments (note 5) | 306 | -6,190 | -2,534 | -5,646 |
| Restructuring expenses (note 17) | - | - | 0 | - |
| Non-cash restructuring expenses (note 11) | - | - | - | 0 |
| Gain on insurance recoveries | - | - | 0 | - |
| Accounts receivable | 72,682 | -29,970 | 5,215 | 40,033 |
| Inventories | -26,129 | 14,663 | 32,133 | -29,863 |
| Prepaid expenses, net deferred income taxes and other current assets | 106,387 | -2,312 | -47,017 | -79,358 |
| Accounts payable, accrued expenses, income taxes payable and other | 10,645 | 7,636 | 49,088 | 63,090 |
| Net cash provided by (used in) operating activities | 339,745 | 457,321 | 538,766 | 578,661 |
| Purchases of property, plant and equipment | 28,539 | 42,965 | 30,585 | 20,796 |
| Patent registration and acquisition costs | 7,351 | - | - | - |
| Purchases of intangible assets | -1,335 | 2,814 | 3,193 | 2,992 |
| Business acquisitions, net of cash acquired | 0 | 522 | 138,578 | 0 |
| Purchases of investments (note 5) | 4,231 | 2,173 | 2,013 | 2,053 |
| Proceeds from exits of investments (note 5) | 250 | 0 | 250 | 0 |
| Proceeds (payments) on maturity of foreign currency contracts | 12,406 | 4,104 | -40,406 | 5,945 |
| Net cash provided by (used in) investing activities | -50,942 | -52,578 | -133,713 | -31,786 |
| Proceeds from issuance of common stock, net | 29,557 | 8,205 | 30,156 | 9,023 |
| Taxes paid related to net share settlement of equity awards | 20,308 | 719 | 590 | 364 |
| Purchases of treasury stock | 175,014 | 150,010 | 100,008 | 75,026 |
| Payments of business combination contingent consideration | 0 | 0 | 0 | 0 |
| Acquisition of consolidated subsidiary | - | - | 10,855 | - |
| Proceeds from borrowings, net of borrowing costs | - | - | 0 | 0 |
| Repayment of borrowings | 5,000 | 0 | 5,000 | 0 |
| Dividends paid | 87,584 | 87,750 | 77,590 | 77,704 |
| Net cash provided by (used in) financing activities | -258,349 | -230,274 | -163,887 | -144,071 |
| Effect of exchange rate changes on cash | 2,767 | -71 | 35,573 | 7,963 |
| Net increase (decrease) in cash and cash equivalents | 33,221 | 174,398 | 276,739 | 410,767 |
| Cash and cash equivalents at beginning of period | 1,383,848 | 1,209,450 | 932,711 | 521,944 |
| Cash and cash equivalents at end of period | 1,417,069 | 1,383,848 | 1,209,450 | 932,711 |
RESMED INC (RMD)
RESMED INC (RMD)